ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1110

Radiologic Progression in Hand Osteoarthritis (OA) Over 2.6 Years – Data From the Sekoia Trial

Emmanuel Maheu1, Christian Cadet2 and Francis Berenbaum1, 1Rheumatology, AP-HP, St Antoine Hospital, Paris, France, 2Rheumatology, Paris, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Assessment, longitudinal studies, osteoarthritis and radiography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Hand OA is a frequent polyarticular disease. Few is known with respect to its radiological progression over time, which in addition is difficult to assess, considering that no radiographic scoring method has, today, proved being superior to another. The goal of this study was to assess hand OA radiological progression over 3 years using three validated scoring methods.

Methods:

Data came from an international 3-year, randomized, placebo-controlled phase III trial designed to assess the effect of strontium ranelate compared to placebo on the radiographic progression of knee OA which included symptomatic primary knee OA patients (ACR criteria) at a Kellgren-Lawrence (KL) grade II or III, with a minimal joint space width (JSW) between 2.5-5 mm. During this trial, baseline and final postero-anterior radiographs of each hand were performed. Symptoms were assessed using the functional index for Hand OA (FIHOA; range 0-30) and the AUSCAN (0-300). Two independent readers scored half of the pairs of radiographs obtained each, blinded to treatment and time sequence, using the KL (range 0-128), Kallman (0-204) and Verbruggen anatomical phase (0-218) scoring methods with a good inter-rater reproducibility. Hand OA radiographic progression was studied in the placebo group by looking at 1/ baseline-end changes in global scores, 2/ the numbers of progressors (progression was defined for each global score by a change over each reader’s smallest detectable difference (SDD)), and 3/ the number of patients in whom at least 1 joint showed a deterioration (from KL0-1 to KL≥2; progression of ≥1 phase for Verbruggen score).

Results:

Of 1669 patients included in the SEKOIA trial, 999 had radiologic hand OA: 73%. 297 patients in the placebo group had baseline and post-baseline radiographs. 72% were female, mean age 64±7 years, body mass index 29.5±5 kg/m², and initial knee JSW 3.5±0.8 mm. Baseline hand OA radiologic severity was mild: KL score 21±13, Kallman score 24±21 and Verbruggen score 13±14. FIHOA score was 4±5, Auscan global score was 96+80. Mean time interval between baseline and final radiographs was 31.5 months.

 Hand OA radiographic progression over 2.6 years was modest with a mean change of 2.4±3.3 for KL score, 3.7±5.3 for Kallman score and 2.0±4.0 for Verbruggen score.

The numbers (%) of progressors (change≥SDD) were 7 (2%), 17 (6%), and 21 (7%) respectively.

The numbers (%) of patients with at least 1 worsened joint were 169 (57%) for KL and 139 (47%) for Verbruggen score, with respective means of 2.0±1.3 and 1.7±1.1 worsening joint.

Conclusion:

Whatever the radiological scoring method used, and the kind of analysis performed, mild radiographic hand OA patients showed a very weak global radiological progression over 2.6 years.       In future structure-modification trials in hand OA, analysing the number of patients with at least one joint worsening could be the most sensitive method.


Disclosure:

E. Maheu,

Expanscience, Genévrier,Genzyme, Pierre Fabre, Rottapharm, Servier. ,

5,

Expanscience, Ibsa-Genévrier, Rottapharm, TRB-Chemedica.,

9;

C. Cadet,

Expanscience, Servier,

5,

Expanscience, Rottapharm,

9;

F. Berenbaum,

Expanscience, Pierre Fabre, Servier, TRB-Chemedica, Rottapharm, Genévrier ,

9.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/radiologic-progression-in-hand-osteoarthritis-oa-over-2-6-years-data-from-the-sekoia-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology